TY - JOUR
T1 - Prediction of on-treatment disability worsening in RRMS with the MAGNIMS score
AU - for the MSBase Study Group
AU - Kunchok, Amy
AU - Lechner-Scott, Jeannette
AU - Granella, Franco
AU - Trojano, Maria
AU - Alroughani, Raed
AU - Sola, Patrizia
AU - Ferraro, Diana
AU - Lugaresi, Alessandra
AU - Onofrj, Marco
AU - Ozakbas, Serkan
AU - Izquierdo, Guillermo
AU - Grammond, Pierre
AU - Luis Sanchez-Menoyo, Jose
AU - Van Wijmeersch, Bart
AU - Boz, Cavit
AU - Pucci, Eugenio
AU - McCombe, Pamela
AU - Grand’Maison, Francois
AU - Spitaleri, Daniele
AU - Vucic, Steve
AU - Hupperts, Raymond
AU - Jokubaitis, Vilija
AU - Sormani, Maria Pia
AU - Butzkueven, Helmut
AU - Kalincik, Tomas
N1 - Ricercatore distaccato presso IRCCS a seguito Convenzione esclusiva con Università di Bologna (Lugaresi Alessandra)
PY - 2020
Y1 - 2020
N2 - Background: The magnetic resonance imaging in multiple sclerosis (MAGNIMS) score combines relapses and magnetic resonance imaging (MRI) lesions to predict disability outcomes in relapsing–remitting multiple sclerosis (RRMS) treated with interferon-β. Objective: To validate the MAGNIMS score and extend to other disease-modifying therapies (DMTs). To examine the prognostic value of gadolinium contrast-enhancing (Gd+) lesions. Methods: This RRMS MSBase cohort study (n = 2293) used a Cox model to examine the prognostic value of relapses, MRI activity and the MAGNIMS score for disability worsening during treatment with interferon-β and three other DMTs. Results: Three new T2 lesions (hazard ratio (HR) = 1.60, p = 0.028) or two relapses (HR = 2.24, p = 0.002) on interferon-β (for 12 months) were predictive of disability worsening over 4 years. MAGNIMS score = 2 (1 relapse and ⩾3 T2 lesions or ⩾2 relapses) was associated with a greater risk of disability worsening on interferon-β (HR = 2.0, p = 0.001). In pooled cohort of four DMTs, similar associations were seen (MAGNIMS score = 2: HR = 1.72, p = 0.001). Secondary analyses demonstrated that the addition of Gd+ to the MAGNIMS did not materially improve its prediction of disability worsening. Conclusion: We have validated the MAGNIMS score in RRMS and extended its application to three other DMTs: 1 relapse and ⩾3 T2 lesions or ⩾2 relapses predicted worsening of disability. Contrast-enhancing lesions did not substantially improve the prognostic score.
AB - Background: The magnetic resonance imaging in multiple sclerosis (MAGNIMS) score combines relapses and magnetic resonance imaging (MRI) lesions to predict disability outcomes in relapsing–remitting multiple sclerosis (RRMS) treated with interferon-β. Objective: To validate the MAGNIMS score and extend to other disease-modifying therapies (DMTs). To examine the prognostic value of gadolinium contrast-enhancing (Gd+) lesions. Methods: This RRMS MSBase cohort study (n = 2293) used a Cox model to examine the prognostic value of relapses, MRI activity and the MAGNIMS score for disability worsening during treatment with interferon-β and three other DMTs. Results: Three new T2 lesions (hazard ratio (HR) = 1.60, p = 0.028) or two relapses (HR = 2.24, p = 0.002) on interferon-β (for 12 months) were predictive of disability worsening over 4 years. MAGNIMS score = 2 (1 relapse and ⩾3 T2 lesions or ⩾2 relapses) was associated with a greater risk of disability worsening on interferon-β (HR = 2.0, p = 0.001). In pooled cohort of four DMTs, similar associations were seen (MAGNIMS score = 2: HR = 1.72, p = 0.001). Secondary analyses demonstrated that the addition of Gd+ to the MAGNIMS did not materially improve its prediction of disability worsening. Conclusion: We have validated the MAGNIMS score in RRMS and extended its application to three other DMTs: 1 relapse and ⩾3 T2 lesions or ⩾2 relapses predicted worsening of disability. Contrast-enhancing lesions did not substantially improve the prognostic score.
KW - magnetic resonance imaging
KW - Multiple sclerosis
KW - outcomes
KW - prediction
KW - prognosis
KW - therapy
UR - http://www.scopus.com/inward/record.url?scp=85087690733&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85087690733&partnerID=8YFLogxK
U2 - 10.1177/1352458520936823
DO - 10.1177/1352458520936823
M3 - Article
AN - SCOPUS:85087690733
JO - Multiple Sclerosis
JF - Multiple Sclerosis
SN - 1352-4585
ER -